Simplify Asset Management Inc. Makes New $397,000 Investment in Capricor Therapeutics, Inc. $CAPR

Simplify Asset Management Inc. bought a new position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the second quarter, Holdings Channel.com reports. The firm bought 40,000 shares of the biotechnology company’s stock, valued at approximately $397,000.

A number of other large investors have also made changes to their positions in the stock. Citizens Financial Group Inc. RI acquired a new position in shares of Capricor Therapeutics during the first quarter worth $95,000. KLP Kapitalforvaltning AS increased its position in shares of Capricor Therapeutics by 65.2% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 4,300 shares during the last quarter. Arizona State Retirement System acquired a new position in shares of Capricor Therapeutics during the first quarter valued at $111,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Capricor Therapeutics by 31.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 3,162 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Capricor Therapeutics during the second quarter valued at approximately $135,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. HC Wainwright restated a “buy” rating and issued a $24.00 price target on shares of Capricor Therapeutics in a research note on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. Finally, Roth Capital cut their price target on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a report on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $5.56 on Tuesday. The company’s 50-day simple moving average is $6.56 and its 200-day simple moving average is $8.32. Capricor Therapeutics, Inc. has a fifty-two week low of $5.43 and a fifty-two week high of $20.75. The stock has a market capitalization of $254.19 million, a P/E ratio of -3.39 and a beta of 0.57.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). On average, research analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.